Daily Issue → inbox:
Series B financing to advance K-1728, a next-generation pan-mutant selective PI3Kα inhibitor designed to selectively inhibit both kinase domain and helical domain PI3Kα mutations while sparing wild-type PI3Kα, for cancer and vascular malformations.